

SB239 INTRODUCED



1 KYD6AA-1
2 By Senator Stutts
3 RFD: Healthcare
4 First Read: 25-Apr-23
5
6 2023 Regular Session



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

SYNOPSIS:

The Medication Assisted Treatment of Opioid Use Act of 2019 ("MAT Act"), requires the Alabama Board of Medical Examiners to adopt rules governing the prescribing and use of medications containing buprenorphine to treat opioid addiction in the nonresidential setting. The rules authorized by The MAT Act relate to dosage, screening, therapy, and record-keeping related to treatment with buprenorphine. A standard working group with members who specialize in addiction is also provided to assist in adoption of the rules.

Since enactment, changes in federal law and policy governing medication-assisted treatment of opioid addiction have created conflicts with the provisions of the MAT Act.

This bill would repeal the MAT Act.

A BILL
TO BE ENTITLED
AN ACT

Relating to Opioid Addiction Treatment; to repeal the Medication Assisted Treatment of Opioid Use Act of 2019,



SB239 INTRODUCED

29 codified as Sections 20-2-300 through 20-2-302, Code of
30 Alabama 1975, that provide for adoption of rules governing use
31 of buprenorphine in the treatment of opioid addiction and a
32 standing working group to assist in drafting the rules.

33 BE IT ENACTED BY THE LEGISLATURE OF ALABAMA:

34 Section 1. Sections 20-2-300 through 20-2-302, Code of
35 Alabama 1975, known as The Medication Assisted Treatment of
36 Opioid Use Act of 2019 and providing for the development and
37 adoption of rules by the Alabama Board of Medical Examiners,
38 with the consultation and assistance of a standing working
39 group, for the treatment of opioid-addicted individuals with
40 buprenorphine in a nonresidential setting, are repealed.

41 Section 2. This act shall become effective on the first
42 day of the third month following its passage and approval by
43 the Governor, or its otherwise becoming law.